Genetic alterations of CCND1 and EMSY in breast cancers

Histopathology

Volumn 52, Issue 6, 2008, Pages 698-705

  Kirkegaard, T ^a,b,c   Nielsen, K V ^b   Jensen, L B ^a   Campbell, F M ^a   Muller S ^b   Tovey, S M ^a   Brown, S ^a   Cooke, T G ^a   Bartlett, J M S ^a,d  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b Dako Danmark A S   (Denmark)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; CCND1; EMSY; FISH

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CCND1 GENE; CONTROLLED STUDY; EMSY GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DELETION; GENE FUNCTION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL;

BREAST NEOPLASMS; COHORT STUDIES; CYCLINS; FEMALE; GENE DOSAGE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; REPRESSOR PROTEINS; TAMOXIFEN;

EID: 42649110664     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03007.x     Document Type: Article

References (27)

1. Karlseder J, Zeillinger R, Schneeberger C et al. Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes chromosomes. Cancer 1994 9 42 48.
2. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res. Treat. 2003 78 323 335.
3. Albertson DG. Gene amplification in cancer. Trends Genet. 2006 22 447 455.
4. Rodriguez C, Hughes-Davies L, Valles H et al. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin. Cancer Res. 2004 10 5785 5791.
5. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004 18 2699 2711.
6. Neuman E, Ladha MH, Lin N et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell. Biol. 1997 17 5338 5347.
7. Zwijsen RM, Wientjens E, Klompmaker R, van der SJ, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997 88 405 415.
8. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev. 1998 12 3488 3498.
9. Bernards R. CDK-independent activities of D type cyclins. Biochim. Biophys. Acta 1999 1424 M17 M22.
10. van Diest PJ, Michalides RJ, Jannink L et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am. J. Pathol. 1997 150 705 711.
11. Musgrove EA, Lee CS, Buckley MF, Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl Acad. Sci. U.S.A. 1994 91 8022 8026.
12. Jirstrom K, Stendahl M, Ryden L et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res. 2005 65 8009 8016.
13. Kilker RL, Hartl MW, Rutherford TM, Planas-Silva MD. Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells. J. Steroid Biochem. Mol. Biol. 2004 92 63 71.
14. Al-Kuraya K, Schraml P, Torhorst J et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 2004 64 8534 8540.
15. Reis-Filho JS, Savage K, Lambros MB et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod. Pathol. 2006 19 999 1009.
16. Bieche I, Olivi M, Nogues C, Vidaud M, Lidereau R. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br. J. Cancer 2002 86 580 586.
17. Kenny FS, Hui R, Musgrove EA et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin. Cancer Res. 1999 5 2069 2076.
18. Naidu R, Wahab NA, Yadav MM, Kutty MK. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Oncol. Rep. 2002 9 409 416.
19. Bostner J, Ahnstrom WM, Fornander T, Skoog L, Nordenskjold B, Stal O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 2007 26 6997 7005.
20. Hofmann W, Schlag PM. BRCA1 and BRCA2-breast cancer susceptibility genes. J. Cancer Res. Clin. Oncol. 2000 126 487 496.
21. Yao J, Polyak K. EMSY links breast cancer gene 2 to the 'Royal Family'. Breast Cancer Res. 2004 6 201 203.
22. Hughes-Davies L, Huntsman D, Ruas M et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003 115 523 535.
23. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin. Cancer Res. 2005 11 4835 4842.
24. Schuuring E, Verhoeven E, van Tinteren H et al. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res. 1992 52 5229 5234.
25. Knoop AS, Knudsen H, Balslev E et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 2005 23 7483 7490.
26. Olsen KE, Knudsen H, Rasmussen BB et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol. 2004 43 35 42.
27. Bekri S, Adelaide J, Merscher S et al. Detailed map of a region commonly amplified at 11q13→q14 in human breast carcinoma. Cytogenet. Cell Genet. 1997 79 125 131.